Multimodal evaluation of 19F-BPA internalization in pancreatic cancer cells for boron capture and proton therapy potential applications

•19F-BPA is significantly internalized in PANC-1 cells.•At 120 ppm of 11B 19F-BPA has an internalization ratio equal to 0.5.•19F-MRS can detect and quantify the therapeutic 19F-BPA doses useful in BNCT/PBFT.•19F-BPA is a promising BNCT/PBFT carrier and tracer for the treatment of pancreatic cancer....

Full description

Saved in:
Bibliographic Details
Published in:Physica medica 2022-02, Vol.94, p.75-84
Main Authors: Ciardiello, Andrea, Altieri, Saverio, Ballarini, Francesca, Bocci, Valerio, Bortolussi, Silva, Cansolino, Laura, Carlotti, Daniele, Ciocca, Mario, Faccini, Riccardo, Facoetti, Angelica, Ferrari, Cinzia, Ficcadenti, Luca, Furfaro, Emiliano, Giagu, Stefano, Iacoangeli, Francesco, Macioce, Giampiero, Mancini-Terracciano, Carlo, Messina, Andrea, Milazzo, Luisa, Pacifico, Severina, Piccolella, Simona, Postuma, Ian, Rotili, Dante, Vercesi, Valerio, Voena, Cecilia, Vulcano, Francesca, Capuani, Silvia
Format: Article
Language:English
Subjects:
19F-BPA
Boron neutron capture therapy
Magnetic resonance spectroscopy
Proton boron fusion therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•19F-BPA is significantly internalized in PANC-1 cells.•At 120 ppm of 11B 19F-BPA has an internalization ratio equal to 0.5.•19F-MRS can detect and quantify the therapeutic 19F-BPA doses useful in BNCT/PBFT.•19F-BPA is a promising BNCT/PBFT carrier and tracer for the treatment of pancreatic cancer. One of the obstacles to the application of Boron Neutron Capture Therapy (BNCT) and Proton Boron Fusion Therapy (PBFT) concerns the measurement of borated carriers' biodistribution. The objective of the present study was to evaluate the in vitro internalization of the 19F-labelled p-boronophenylalanine (19F-BPA) in the human cancer pancreatic cell line (PANC-1) for the potential application of BNCT and PBFT in pancreatic cancer. The 19F-BPA carrier has the advantage that its bio-distribution may be monitored in vivo using 19F-Nuclear Magnetic Resonance (19F NMR). The 19F-BPA internalization in PANC-1 cells was evaluated using three independent techniques on cellular samples left in contact with growing medium enriched with 13.6 mM 19F-BPA corresponding to a 11B concentration of 120 ppm: neutron autoradiography, which quantifies boron; liquid chromatography hyphenated to tandem mass spectrometry and UV-Diode Array Detection (UV-DAD), which quantifies 19F-BPA molecule; and 19F NMR spectroscopy, which detects fluorine nuclei. Our studies suggested that 19F-BPA is internalized by PANC-1 cells. The three methods provided consistent results of about 50% internalization fraction at 120 ppm of 11B. Small variations (less than 15%) in internalization fraction are mainly dependent on the proliferation state of the cells. The ability of 19F NMR spectroscopy to study 19F-BPA internalization was validated by well-established independent techniques. The multimodal approach we used suggests 19F-BPA as a promising BNCT/PBFT carrier for the treatment of pancreatic cancer. Since the quantification is performed at doses useful for BNCT/PBFT, 19F NMR can be envisaged to monitor 19F-BPA bio-distribution during the therapy.
ISSN:1120-1797
1724-191X
DOI:10.1016/j.ejmp.2021.12.011